MY163110A - Use of toll-like receptor and agonist for treating cancer - Google Patents
Use of toll-like receptor and agonist for treating cancerInfo
- Publication number
- MY163110A MY163110A MYPI2012001519A MYPI2012001519A MY163110A MY 163110 A MY163110 A MY 163110A MY PI2012001519 A MYPI2012001519 A MY PI2012001519A MY PI2012001519 A MYPI2012001519 A MY PI2012001519A MY 163110 A MY163110 A MY 163110A
- Authority
- MY
- Malaysia
- Prior art keywords
- toll
- receptor
- treating cancer
- agonist
- effect
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 102000002689 Toll-like receptor Human genes 0.000 title abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 102000008234 Toll-like receptor 5 Human genes 0.000 abstract 2
- 108010060812 Toll-like receptor 5 Proteins 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108010040721 Flagellin Proteins 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 230000005775 apoptotic pathway Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000003970 toll like receptor agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24925309P | 2009-10-06 | 2009-10-06 | |
| US24959609P | 2009-10-07 | 2009-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY163110A true MY163110A (en) | 2017-08-15 |
Family
ID=43857117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012001519A MY163110A (en) | 2009-10-06 | 2010-10-06 | Use of toll-like receptor and agonist for treating cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205095B2 (enExample) |
| EP (1) | EP2486134B1 (enExample) |
| JP (2) | JP5796014B2 (enExample) |
| KR (1) | KR20120104177A (enExample) |
| CN (1) | CN104136614B (enExample) |
| AP (1) | AP2012006253A0 (enExample) |
| AU (1) | AU2010303464B2 (enExample) |
| BR (1) | BR112012011331B8 (enExample) |
| CA (1) | CA2777198C (enExample) |
| EA (1) | EA021842B1 (enExample) |
| ES (1) | ES2457518T3 (enExample) |
| IL (1) | IL219060A (enExample) |
| MX (1) | MX2012004095A (enExample) |
| MY (1) | MY163110A (enExample) |
| WO (1) | WO2011044246A1 (enExample) |
| ZA (1) | ZA201202500B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069198A1 (en) | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| ES2412237T3 (es) | 2008-08-01 | 2013-07-10 | Cleveland Biolabs, Inc. | Métodos para tratar lesiones por reperfusión |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| WO2014098649A1 (en) * | 2012-12-18 | 2014-06-26 | Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" | Compositions and methods using toll-like receptor 5 and toll-like receptor agonist |
| WO2015080631A1 (en) * | 2013-11-27 | 2015-06-04 | Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" | Improved expression vector for toll-like receptor and agonist and use for treating cancer |
| ES2816630T3 (es) * | 2014-07-30 | 2021-04-05 | Genome Prot Inc | Composiciones de flagelina y usos |
| JP6423889B2 (ja) | 2014-10-07 | 2018-11-14 | サイトリミック株式会社 | Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
| US10183056B2 (en) | 2014-10-16 | 2019-01-22 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| EP3269733B1 (en) | 2015-03-09 | 2020-06-17 | Cytlimic Inc. | Peptide derived from gpc3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells |
| US10842848B2 (en) * | 2015-04-07 | 2020-11-24 | Cytlimic Inc. | Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein |
| KR101634380B1 (ko) | 2015-06-23 | 2016-06-28 | 한국생산기술연구원 | Tlr5 아고니스트 단백질의 생산방법 |
| CN105801709B (zh) * | 2016-04-29 | 2019-10-08 | 北京纽莱福生物科技有限公司 | CBLB502-Fc融合蛋白及其制备方法 |
| EP3527216B1 (en) | 2016-10-11 | 2024-02-14 | NEC Corporation | A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide |
| RU2741228C2 (ru) * | 2016-11-14 | 2021-01-22 | Общество С Ограниченной Ответственностью "Панацела Лабс" | Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора |
| US11029609B2 (en) * | 2016-12-28 | 2021-06-08 | Asml Netherlands B.V. | Simulation-assisted alignment between metrology image and design |
| CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| EP3668529A4 (en) | 2017-07-20 | 2021-07-14 | Spogen Biotech Inc. | BIOACTIVE POLYPEPTIDES ALLOWING IMPROVEMENTS IN PROTECTION, GROWTH AND PRODUCTIVITY OF PLANTS |
| LT3768284T (lt) | 2018-03-19 | 2022-04-11 | 4D Pharma Research Limited | Enterecoccus flagelino kompozicijos, skirtos panaudoti terapijai |
| US12440536B2 (en) | 2018-05-18 | 2025-10-14 | The University Of Hong Kong | Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof |
| WO2020163370A1 (en) | 2019-02-04 | 2020-08-13 | Codiak Biosciences, Inc. | Membrane protein scaffolds for exosome engineering |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
| EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
| EP4121450A2 (en) | 2020-03-20 | 2023-01-25 | Codiak BioSciences, Inc. | Extracellular vesicles for therapy |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| EP4620482A1 (en) * | 2024-03-18 | 2025-09-24 | Istituto Europeo di Oncologia S.r.l. | Flagellin-related peptides and uses thereof |
| WO2025196053A1 (en) * | 2024-03-18 | 2025-09-25 | Istituto Europeo Di Oncologia S.R.L. | Flagellin-related peptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703146B2 (en) * | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| US8580321B2 (en) * | 2003-12-02 | 2013-11-12 | The Cleveland Clinic Foundation | Method for reducing the effects of chemotherapy using flagellin related polypeptides |
| WO2006069198A1 (en) * | 2004-12-22 | 2006-06-29 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| JP2008527009A (ja) * | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
-
2010
- 2010-10-06 MY MYPI2012001519A patent/MY163110A/en unknown
- 2010-10-06 JP JP2012533282A patent/JP5796014B2/ja not_active Expired - Fee Related
- 2010-10-06 CA CA2777198A patent/CA2777198C/en active Active
- 2010-10-06 AP AP2012006253A patent/AP2012006253A0/xx unknown
- 2010-10-06 KR KR1020127008759A patent/KR20120104177A/ko not_active Ceased
- 2010-10-06 AU AU2010303464A patent/AU2010303464B2/en not_active Ceased
- 2010-10-06 EP EP10822611.9A patent/EP2486134B1/en active Active
- 2010-10-06 US US13/500,552 patent/US9205095B2/en active Active
- 2010-10-06 CN CN201080055226.1A patent/CN104136614B/zh not_active Expired - Fee Related
- 2010-10-06 EA EA201290140A patent/EA021842B1/ru unknown
- 2010-10-06 ES ES10822611.9T patent/ES2457518T3/es active Active
- 2010-10-06 MX MX2012004095A patent/MX2012004095A/es active IP Right Grant
- 2010-10-06 WO PCT/US2010/051646 patent/WO2011044246A1/en not_active Ceased
- 2010-10-06 BR BR112012011331A patent/BR112012011331B8/pt not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219060A patent/IL219060A/en active IP Right Grant
- 2012-04-05 ZA ZA2012/02500A patent/ZA201202500B/en unknown
-
2015
- 2015-06-26 JP JP2015128384A patent/JP2015165821A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012011331B8 (pt) | 2021-05-25 |
| BR112012011331A2 (pt) | 2015-09-15 |
| KR20120104177A (ko) | 2012-09-20 |
| EA201290140A1 (ru) | 2012-11-30 |
| ZA201202500B (en) | 2013-06-26 |
| AP2012006253A0 (en) | 2012-06-30 |
| BR112012011331B1 (pt) | 2021-03-02 |
| AU2010303464B2 (en) | 2014-05-01 |
| IL219060A0 (en) | 2012-06-28 |
| AU2010303464A1 (en) | 2012-04-12 |
| ES2457518T3 (es) | 2014-04-28 |
| WO2011044246A1 (en) | 2011-04-14 |
| JP2013506437A (ja) | 2013-02-28 |
| EP2486134A4 (en) | 2013-02-13 |
| HK1199058A1 (en) | 2015-06-19 |
| CA2777198C (en) | 2018-07-24 |
| JP2015165821A (ja) | 2015-09-24 |
| CN104136614A (zh) | 2014-11-05 |
| CN104136614B (zh) | 2018-04-06 |
| US9205095B2 (en) | 2015-12-08 |
| MX2012004095A (es) | 2012-09-12 |
| US20120208871A1 (en) | 2012-08-16 |
| EP2486134B1 (en) | 2014-01-08 |
| EA021842B1 (ru) | 2015-09-30 |
| IL219060A (en) | 2017-02-28 |
| JP5796014B2 (ja) | 2015-10-21 |
| EP2486134A1 (en) | 2012-08-15 |
| CA2777198A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY163110A (en) | Use of toll-like receptor and agonist for treating cancer | |
| EA201390843A1 (ru) | Применение агониста toll-подобного рецептора для лечения рака | |
| EA201270356A1 (ru) | Иммуногенные композиции, содержащие модуляторы активности tlr | |
| MX2012002654A (es) | Compuestos y composiciones como moduladores de la actividad de tlr. | |
| NZ604510A (en) | Dilutable biocidal compositions and methods of use | |
| CL2015001389A1 (es) | Composiciones y compuestos antihelmínticos y métodos para usarlos. | |
| PH12018501515A1 (en) | Parenteral novovirus vaccine formulations | |
| TN2015000353A1 (en) | Newcastle disease viruses and uses thereof | |
| GT201300319A (es) | Coagonistas del receptor de glucagón / glp-1 | |
| CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| MX340090B (es) | Analogos de spliceostatina. | |
| TN2013000310A1 (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
| PH12016502132B1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| MX337577B (es) | Anticuerpos c-kit y usos de los mismos. | |
| MX341395B (es) | Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc. | |
| UY34381A (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| MX2016008226A (es) | Metodos para el cuidado oral prebiotico usando un sacarido. | |
| NZ702415A (en) | Methods for treating neutropenia using retinoid agonists | |
| SG178596A1 (en) | Methods of treatment using anti-oxidized ldl antibodies | |
| MY169687A (en) | Component and method for treating viral disease | |
| EA201592056A1 (ru) | Высококонцентрированные составы растворимых fc-рецепторов | |
| NZ612843A (en) | Pheromone composition | |
| PH12013501422A1 (en) | Use of toll-like receptor agonist for treating cancer | |
| UA110605C2 (uk) | Застосування toll-подібного рецептора і агоніста toll-подібного рецептора для лікування раку |